GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ ELLIPTA™ for the treatment ...
The EMA’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for Relvar Ellipta, a combination of the inhaled corticosteroid fluticasone ...
LONDON, UK, 20 September, 2013 - Skyepharma PLC (LSE: SKP), the expert oral and inhalation drug delivery company, announces that the regulatory committee (Bunka-Kai) of the Japanese Ministry of Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback